SISRAM MED (01696) declined nearly 5% again, following yesterday's plunge of over 13%. As of press time, the stock was down 4.81% to HK$5.74, with a trading volume of HK$16.5645 million.

On the news front, SISRAM MED recently released its interim results for 2025, reporting revenue of US$165 million, down 1.9% year-on-year, and profit attributable to owners of the parent company of US$6.426 million, down 41.3% year-on-year.

The announcement indicated that the group's revenue decline during the period was mainly attributed to challenging conditions in the North American market, including high interest rates and weak consumption. Additionally, transportation restrictions due to regional tensions in June resulted in slight delays in revenue recognition. Excluding the adverse factors in the North American market, SISRAM MED's international markets achieved 7.1% growth compared to the same period in 2024.

Shenwan Hongyuan noted that the company's North American market was impacted by high interest rates and weak consumption, leading to significant revenue decline that dragged down overall performance, while international markets outside North America achieved 7.1% growth through direct sales office deployment. The firm believes that as a leading energy-based aesthetic medical device company, the company leverages its direct sales network to strengthen its Asia-Pacific advantages, with injectable filler business opening a second growth curve. Short-term North American headwinds do not change the long-term logic, and the listing of Daxifi and the volume expansion of combination therapy ecosystem are expected to drive performance recovery in the second half of the year.